SCHEMBL243663

SCHEMBL243663

CN(C(=O)C1CCCCC1)[C@H]1CCCCNC1=O

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 4/20 0.49
PSEN1 P49768 14/20 0.42
PSEN2 P49810 14/20 0.42
APH1B Q8WW43 14/20 0.42
NCSTN Q92542 14/20 0.42
APH1A Q96BI3 14/20 0.42
PSENEN Q9NZ42 14/20 0.42
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16059343 0.85 CCR2 (0.36) CCR2
SCHEMBL4618066 0.80 CCR2 (0.38) CCR2PSEN1PSEN2APH1BNCSTN
Methyl Alcohol SCHEMBL28457179 0.78 PSEN1 (0.45) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL3033354 0.77 PSEN1 (0.47) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL3033357 0.77 PSEN1 (0.47) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL6263593 0.76 CCR2 (0.41) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL29346027 0.76 PSEN1 (0.44) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL4188392 0.76 L3MBTL1 (0.44) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL4186722 0.74 CCR2 (0.44) CCR2PSEN1PSEN2APH1BNCSTN
SCHEMBL3108291 0.74 MGLL (0.40) CCR2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896036-A1 ANTI-INFLAMMATORY AGENTS Cambridge Enterprise Limited (GB) 2008-03-12 EP claimed
WO-2006134384-A1 ANTI-INFLAMMATORY AGENTS CAMBRIDGE ENTERPRISE LIMITED (GB) 2006-12-21 WO claimed
EP-2401610-A1 METHODS FOR IDENTIFICATION Cambridge Enterprise Ltd. (GB) 2012-01-04 EP disclosed
US-7803794-B2 Anti-inflammatory agents CAMBRIDGE ENTERPRISE LIMITED (GB) 2010-09-28 US disclosed
WO-2010097591-A1 METHODS FOR IDENTIFICATION CAMBRIDGE ENTERPRISE LIMITED (GB) 2010-09-02 WO disclosed
US-20100016286-A1 Anti-Inflammatory Agents CAMBRIDGE ENTERPRISE LIMITED (GB) 2010-01-21 US disclosed
EP-1896036-A1 ANTI-INFLAMMATORY AGENTS Cambridge Enterprise Limited (GB) 2008-03-12 EP disclosed
EP-1896036-A1 ANTI-INFLAMMATORY AGENTS Cambridge Enterprise Limited (GB) 2008-03-12 EP disclosed
WO-2006134384-A1 ANTI-INFLAMMATORY AGENTS CAMBRIDGE ENTERPRISE LIMITED (GB) 2006-12-21 WO disclosed
WO-2006134384-A1 ANTI-INFLAMMATORY AGENTS CAMBRIDGE ENTERPRISE LIMITED (GB) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016286-A1 Anti-Inflammatory Agents TNF, LTC4S, IL6 CCR2 54/4885PSEN1 3780/4885PSEN2 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.